# An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.

> **NCT03084471** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 867 (actual)

## Conditions studied

- Advanced Solid Malignancies

## Interventions

- **BIOLOGICAL:** MEDI4736 (Durvalumab)
- **BIOLOGICAL:** MEDI4736 (Durvalumab) + Tremelimumab

## Key facts

- **NCT ID:** NCT03084471
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-05
- **Primary completion:** 2020-03-31
- **Final completion:** 2022-12-16
- **Target enrollment:** 867 (ACTUAL)
- **Last updated:** 2022-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03084471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03084471, "An Open-Label, Multi-Centre, Study to Assess the Safety of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT03084471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*